PET positivity in AML, however, may be exploited to identify candidates for disrupting CXCR4/CXCL12 interactions, such as plerixafor as an adjunct to chemotherapeutic regimens (59,60). The gene discussed is CXCR4; the disease is acute myeloid leukemia.